Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Survival Benefit in Another Erbitux Trial for Advanced NSCLC Reported
Author
Howard (Jack) West, MD

Although it’s only a leak from a “reliable source”, news came yesterday (link here) about a new lung cancer development from a financial source (yet another example of us learning oncology from Wall Streeters). Specifically, we heard that the BMS-099 that I described in a prior post is actually demonstrating a significant benefit in overall survival (OS). To summarize the BMS-099 trial, it’s one that compared standard chemo of carboplatin/taxane (either taxol (paclitaxel) or taxotere (docetaxel) at the physician’s discretion) with or without the EGFR inhibitor Erbitux (cetuximab), which is an IV monoclonal antibody and “targeted therapy” in a population of patients with previously untreated advanced NSCLC. The schema is as shown here.

BMS 099 Schema

The initial press release about the BMS-099 trial was less favorable, but overall a little puzzling. As described in my initial post about it back in August of 2007, the trial was large, with 676 patients who were not restricted by EGFR markers like protein expression (by immunohistochemistry, or IHC) or gene amplification (by fluorescence in situ hybridization, or FISH); some trials have restricted enrollment to patients with postivie EGFR IHC or FISH tests, in order to increase the chance of showing good results with an EGFR inhibitor. BMS-099 was designed to look at progression-free survival (PFS) by the investigators but also with an independent radiology review board (IRRB). The preliminary results of that trial, as reported by Dr. Tom Lynch from Massachusetts General Hospital back in September at the World Conference on Lung Cancer in Korea (abstract here), showed that the IRRB did not find a significant improvement in PFS, but the investigators did (PFS and response rate (RR) are examples of “soft endpoints” that may somewhat subjective based on what you want or expect; hence the IRRB that shouldn’t have any biases based on expectations of who received an investigational drug). In contrast, the reverse was true for RR, where investigators found a non-significantly higher RR in chemo/erbitux recipients, but the IRRB noted a statistically significant difference. Here’s a summary of what we learned:

BMS 099 Prelim Results

Go figure. So it’s hard to call this a clearly negative trial, even if it didn’t technically meet its primary endpoint.

At the time of the initial presentation by Dr. Lynch, we didn’t have OS results. Now, however, with at least a reliable leak that survival will be significantly better in chemo/erbitux recipients (and survival tends to be a “hard endpoint” with no controversy between investigators and independent reviewers), we’ve got another trial that adds to the “FLEX” trial I’ve described in another post and that we are told also shows a survival benefit for chemo/erbitux vs. chemo alone (this trial, done in Europe, uses cisplatin/navelbine (vinorelbine)). We haven’t received any details about that trial, either, but as a reflection of the importance of a positive large randomized trial in first line treatment of advanced NSCLC, it’s penciled in to be presented at the ASCO Plenary Session, where the most important cancer trials of the meeting are discussed.

There’s no question we need to see the data and not just go by press releases and Wall Street rumors, but it’s reassuring to see multiple trials with different chemo regimens and done in different parts of the world all showing similar results. We now have the FLEX trial with cisplatin/navelbine and done in Europe, the BMS-099 trial with carbo/taxane (taxol or taxotere) and done largely in the US, and finally a trial I described in a prior post with platinum (cisplatin or carboplatin with gemcitabine) that was done largely in Canada, all showing the same finding of superior survival with chemo and concurrent erbitux. This conclusion is particularly interesting to me because it appears that the intravenous monoclonal antibodies can be effective when given concurrently with standard chemo, which is unlike what we’ve generally seen with chemo and the oral small molecule tyrosine kinase inhibitors like tarceva (erlotinib) and iressa (gefitinib).

Coming in the wake of the reported absence of a survival benefit for avastin in the first line AVAiL trial of cisplatin/gemcitabine with avastin (bevacizumab) or placebo, I think it’s quite likely that our views of current “best” treatment, or standard of care, will continue to develop for first line treatment of advanced NSCLC. It’s important also to recognize that many patients are not eligible for avastin because of brain metastases, squamous tumors, blood thinners and other restrictions, so chemo/erbitux may be a clear best choice for these populations, at least until we learn more about the safety of avastin here. But putting it all together, and knowing that we’re still looking for the factors that will help us predict which patients will be the major beneficiaries of erbitux and which ones may get little or no benefit, I’d bet that we’re going to be hashing out new standards of care for advanced NSCLC for a good while.

Next Previous link

Previous PostNext Post

Related Content

Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments. To watch the complete playlist click here.
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.

Forum Discussions

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

JOIN THE CONVERSATION
Hi Amber, Welcome to Grace. …
By JanineT GRACE … on
Could you
By Maeve785 on
It sounds like you’re…
By Dr West on
Thank you Janine
By blaze100 on